General
Preferred name
ETIDRONIC ACID
Synonyms
ETIDRONATE DISODIUM ()
Etidronate ()
HEDPA ()
HEDP ()
Didronel ()
Etidronic acid, disodium salt ()
Etidronate (Didronel) ()
Etidronic acid,60% in water ()
Etidronic acid (disodium) ()
Etidronate (disodium) ()
HEDPA (disodium) ()
HEDP (disodium) ()
Didronel, EHDP, Etidronic acid ()
Sodium etidronate ()
Etidronate (sodium salt) ()
Didronel IV ()
Turpinal 2nz ()
Disodium etidronate ()
NSC-759157 ()
Didronel PMO ()
Etidronic acid disodium salt ()
Acido etidronico ()
Acide etidronique ()
NSC-227995 ()
M05BA01 ()
P&D ID
PD009821
CAS
2809-21-4
100511-44-2
187285-10-5
7414-83-7
Tags
available
drug
Approved by
FDA
First approval
1977
Drug indication
Bone disease
Osteoporosis
Paget's disease
Drug Status
approved
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
PRICE
29
DESCRIPTION
Etidronic acid is a bisphosphonate drug.
(GtoPdb)
DESCRIPTION
Etidronic acid (Etidronate) is an orally and intravenously active bisphosphonate. Etidronic acid inhibits resorption of bone, reduces arterial calcification and can be used for osteoporosis research. Etidronic acid has anticancer activity. Etidronic acid is a chelating agent and can be used to remove heavy metal in water[1][2][3][4].
PRICE
29
DESCRIPTION
Sodium etidronate (Didronel) is a synthetic therapeutic diphosphonate analog of endogenous pyrophosphate. As a member of the family of drugs known as bisphosphonates, Sodium etidronate differs from endogenous pyrophosphate in its resistance to enzymatic hydrolysis. This agent adsorbs to hydroxyapatite cells and reduces the number of osteoclasts, thereby inhibiting abnormal bone resorption. Etidronate may also directly stimulate bone formation by osteoblasts.
(TargetMol Bioactive Compound Library)
DESCRIPTION
Etidronate (Didronel) is a human protein tyrosine phosphatase inhibitor with IC50 of 0.2 μM.
(BOC Sciences Bioactive Compounds)
DESCRIPTION
Etidronate is a non-aminobisphosphonate. It shows protein tyrosine phosphatase inhibitory activity. Etidronate is indicated to treat Paget's disease of bone, as well as the treatment and prevention of heterotropic ossification after total hip replacement of spinal cord injury.
(Enamine Bioactive Compounds)
DESCRIPTION
Etidronic acid (HEDP) is a diphosphonate which affects calcium metabolism. It inhibits ectopic calcification and slows down bone resorption and bone turnover.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
0
Organisms
2
Compound Sets
22
BOC Sciences Bioactive Compounds
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMatrix
Enamine Bioactive Compounds
Enamine BioReference Compounds
Guide to Pharmacology
NPC Screening Collection
ReFrame library
Selleckchem Bioactive Compound Library
The Spectrum Collection
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
62
Molecular Weight
205.97
Hydrogen Bond Acceptors
3
Hydrogen Bond Donors
5
Rotatable Bonds
2
Ring Count
0
Aromatic Ring Count
0
cLogP
-0.99
TPSA
135.29
Fraction CSP3
1.0
Chiral centers
0.0
Largest ring
0.0
QED
0.37
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
Apoptosis
HAP
protein tyrosine phosphatase(PTP)
V-type proton ATPase catalytic subunit
ATP6V1A, PTPRS
phosphatase
MOA
tyrosinase inhibitor
bone resorption inhibitor
Indication
Paget's disease, heterotopic ossification
Disease Area
endocrinology, orthopedics
Therapeutic Class
Bone Density Conservation Agents
Pathway
Metabolism
Microbiology/virology
Source data
